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1. Introduction 
The unpleasant sensation of pain is experienced by all human beings at a given point in life. 
When pain gets severe and/or chronic it requires medical treatment. For over a thousand 
years, opioid agonists have been employed therapeutically to treat pain, with the first 
reports of such use involving the alkaloid morphine dated to the second century 
B.C.(Waldhoer, Bartlett et al. 2004)  The term opioid refers to any substance with opium-like 
activity. Opium is extracted from the juice of the poppy plant Papaver somniferum. Opium 
contains in excess of 20 different alkaloids, and for centuries its crude form was used for 
pain management and for its psychological effects. In 1806 the German pharmacist Sertürner 
isolated a pure substance from opium, which he called morphine after the Greek god of 
dreams, Morpheus. Thereafter other alkaloids such as codeine (1832) and papaverine (1848) 
were isolated.(Reisine and Pasternak 1996) These discoveries paved the way for the use of 
pure alkaloids as opposed to crude opium in the medical profession. It became apparent 
that these alkaloids had a high potential for abuse and addiction. However, it was not until 
1973 that the first descriptions of the pharmacological properties of morphine, along with 
other agonists and antagonists, at the level of the receptor were reported.(Pert, Pasternak et 
al. 1973) 
Opioid receptors are of therapeutic relevance because they constitute the primary targets in 
the clinical treatment of both acute and chronic pain. They are members of the superfamily 
of seven helix transmembrane (TM) proteins known as G-protein coupled receptors 
(GPCRs); so-called because they are coupled in the cytoplasmic side to a group of Gi/Go 
hetero-trimeric proteins called G-proteins: Gǂ, Gǃ and GǄ.(Eguchi M 2004) Currently four 
types of opioid receptors have been identified:  (mu for morphine),  (kappa for 
ketocyclazocine),  (delta for deferens given that it was originally discovered in the vas 
deferens of mice)(Waldhoer, Bartlett et al. 2004) and orphan opioid receptor-like 1. They are 
in turn sub-divided into additional subtypes on the basis of their ligand binding and 
pharmacological profiles: 1-2, 1-3, and 1-2.(Pasternak 1993; Blakeney, Reid et al. 2007) 
The ,  and  main types are the most studied, each playing a different role in pain 
sedation: the -receptor generates the most profound analgesia, but is also associated with 
constipation, respiratory depression, euphoria, tolerance, dependence and 
addition;(Schmauss and Yaksh 1984; Cowan, Zhu et al. 1988)  the -receptor is involved in 
pain relief from thermal sources,(Mansour, Khachaturian et al. 1988) but like the μ-receptor, 
it is also associated with respiratory depression and addiction;(Abdelhamid, Sultana et al. 
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1991; Maldonado, Negus et al. 1992) the -receptor mediates pain originating from chemical 
stimuli,(Leighton, Johnson et al. 1987; Wollemann, Benyhe et al. 1993) but it promotes 
dysphoria, diuresis and sedation.(von Voigtlander, Lahti et al. 1983; Lahti, Mickelson et al. 
1985) There is also evidence that opioid receptors exist as homo- or hetero-oligomeric 
complexes and that their pharmacological responses may be cross-modulated.(Zhu, King et 
al. 1999; Rutherford, Wang et al. 2008) For instance, Waldhoer M et al. used 6’-GNTI to 
demonstrate the existence of a ǅ-κ hetero-dimer in vivo.(Waldhoer, Fong et al. 2005) 
Furthermore, ǅ-opioid antagonists suppress some of the side effects of -opioid agonists 
such as dependence and tolerance while retaining their analgesic properties.(Ananthan 
2006) The realization of this potential for cross-modulation generated interests in developing 
so-called bivalent ligands of opioid receptors.(Dietis, Guerrini et al. 2009; Balboni, Salvadori 
et al. 2011) One therapeutic relevance of opioid receptors worth mentioning is that opioid 
receptors antagonists such as naloxone are utilized clinically in the treatment of morphine 
and heroin addiction and overdose.(Blakeney, Reid et al. 2007) In this chapter, we 
summarize structural aspects of opioid receptors and opioid receptor ligands, with special 
emphasis on the -opioid receptor. The importance of the combined use of experimental 
information and computational models is highlighted. 
 
 
Fig. 1. (A) The three domains of the μ-opioid receptor. Intracellular serine, threonine and 
tyrosine residues are shown in red. (B) Extracellular perspective: the seven transmembrane 
helices are arranged sequentially in a counterclockwise direction. The modeled active and 
inactive structures are shown in cyan and tan, respectively. A substantial structural 
difference between the two states can be seen at TM6. (C) Hypothesized outcome of degree 
of ligand-induced receptor endocytosis. Homology models from Pogozheva, I. D., A. L. 
Lomize, et al. (1998), Fowler, C. B. et al. (2004). 
2. Biochemical and biophysical characterization of the μ-opioid receptor 
2.1 Structural studies of the -opioid receptor 
The notion of preferential stabilization of distinct conformational states by agonists and 
non-agonists has been established experimentally and also demonstrated computationally 
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(see Figure1). The experimental studies include: Li et al. (Li, Han et al. 2007) employing 
agonists and inverse-agonists of the muscarinic acetylcholine GPCR; Xu et al. (Xu, Sanz et 
al. 2008) identified inter-residue interaction differences between the active and inactive 
states for the -opioid receptor. From the computational side, molecular dynamics 
simulations studies suggest that -opioid receptor agonists and antagonists bind to the 
receptor with a set of interactions that are specific to each class.(Kolinski and Filipek 2008) 
In addition, MD simulations have been utilized to elucidate an increase in solvent 
exposure of the intracellular domains between helices 3 and 6, and different interactions 
between the arginine of the E/DRY motif for active and inactive GPCRs.(Fanelli and De 
Benedetti 2006) 
2.2 Mechanism of activation of opioid receptors 
To describe the mechanism of activation and action of opioid receptors it suffices to describe 
the cellular assembly of these receptors. Opioid receptors comprise three domains: an 
extracellular N-terminus, seven transmembrane -helices and an intracellular C-terminus, 
Figure 1. The 7TM helices are arranged sequentially in a counter-clockwise manner when 
viewed from the extracellular side, and are linked by loops called EL1, EL2, EL3, IL1, IL2 
and IL3. EL and IL denote extracellular loop and intracellular loop, respectively. Across the 
receptors the intracellular loops share the highest sequence homology (90%), followed by 
TM domains (70%), while the extracellular loops, the N- and C-termini show the greatest 
diversity.(Knapp, Malatynska et al. 1995) Coupling between the receptors and G-proteins 
occurs via the pertussis toxin sensitive Gǂ unit. 
Activation and signaling from opioid receptors by different classes of ligands are regulated 
by a highly conserved mechanism.(Finn and Whistler 2001; Eguchi 2004) They are activated 
naturally by endogenous peptides, but also by exogenous opiates. Agonist-dependent 
opioid receptor activation induces conformational changes in the receptor, which promote 
exchange of Gǂ-bound GDP for unbound GTP, followed by dissociation of the G-proteins 
from the receptor. The Gǂ unit further dissociates from the GǃǄ units. Signal transduction 
occurs via GTP-bound Gǂ inhibiting adenylate cyclase, responsible for producing cyclic 
adenosine monophosphate (cAMP). Down-regulation of cAMP results in the reduction of 
voltage-dependent current and neurotransmitter release.(Eguchi 2004) Moreover, the 
threshold of voltage-dependent ion channels becomes more negative, decreasing inward 
flow of current responsible for spontaneous neuronal activity resulting in a drop in cellular 
excitability. cAMP reduction also leads to a decrease in neurotransmitter release by cAMP-
dependent protein kinase. The Gǃ and GǄ subunits also play key roles in decreasing cell 
excitability by inhibiting voltage-gated Ca2+ channels, hyperpolarizing the membrane and 
up-regulating the conduction of potassium.(Eguchi 2004) These combined decreases in 
neurotransmitter release and excitability are manifested as analgesia. Finally, the inactive 
state is re-constituted when Gǂ-bound GTP is hydrolyzed to GDP, re-association with GǃǄ 
and recoupling with the receptor. 
Numerous experimental approaches have been utilized to investigate GPCR structure and 
activation including: solution and solid-state NMR, fluorescence, IR and UV spectroscopy, 
spin-labeling, site-directed mutagenesis, substituted cysteine accessibility, disulphide cross-
linking, engineering metal-binding sites, and identification of constitutively active 
mutants.(Gether 2000; Meng and Bourne 2001; Parnot, Miserey-Lenkei et al. 2002; Decaillot, 
Befort et al. 2003; Hubbell, Altenbach et al. 2003; Struts, Salgado et al. 2011) Experimentally 
and computationally, the importance of the lipid membrane should be recognized. It is well 
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documented that membrane composition affects receptor function.(Botelho, Gibson et al. 
2002; Botelho, Huber et al. 2006) From the computational side, molecular dynamics 
simulations showed that the modification of the original positioning of the lipids in the 
membrane influences the dynamics of the protein.(Lau, Grossfield et al. 2007) In addition, 
water flux though the transmembrane helices, has been proposed to affect rhodopsin 
activation. (Grossfield, Pitman et al. 2008)  Lastly, the time scale involved in the activation of 
GPCRs is a challenging task. However, the combined use of computer power and 
experimental information allows for the generation of detailed structural information. For 
instance, 2000 ns molecular dynamics simulations and solid-state 2H-NMR data were 
combined to elucidate the protonation state of key residues directly involved in rhodopsin 
activation.(Martinez-Mayorga, Pitman et al. 2006)  This exemplifies how computational 
models can provide detailed structural information not available otherwise.  
Advances in crystallography and molecular engineering have provided the three-dimensional 
structures of a few GPCR’s: rhodopsin,(Palczewski, Kumasaka et al. 2000; Ridge and 
Palczewski 2007; Choe, Kim et al. 2011) -adrenergic receptor,(Kobilka and Schertler 2008) and 
adenosine receptor.(Jaakola, Griffith et al. 2008)  In the absence of experimental structures of 
opioid receptors, the 2.6-Å resolution crystal structure of bovine rhodopsin(Palczewski, 
Kumasaka et al. 2000) has served as a template for generating homology models of these 
receptors,(Pogozheva, Lomize et al. 1998; Fowler, Pogozheva et al. 2004; Fowler, Pogozheva et 
al. 2004; Pogozheva, Przydzial et al. 2005)  Like rhodopsin, opioid receptors belong to class A 
of the GPCR superfamily. The crystallographic structure of the active state of rhodopsin is now 
available (Choe, Kim et al. 2011) and can be contrasted with the large body of literature that 
suggests a common active conformation among the class-A GPCRs. (Karnik, Gogonea et al. 
2003) In the activated state TM6 undergoes outward rigid-body translation toward TM5, but 
away from TM3 and TM7. As a result, a cavity opens up in the intracellular domain in contact 
with G-proteins. Similar movements have been also suggested for TM1-3 and TM7.(Lin and 
Sakmar 1996; Gether, Lin et al. 1997; Altenbach, Cai et al. 2001) A better understanding of these 
activation mechanisms at the molecular level could lead to new drugs geared towards the 
therapeutic regulation of their functions. 
Decaillot FM et al. applied mutagenesis to study the mechanism of activation of the human 
-opioid receptor.(Decaillot, Befort et al. 2003) By analyzing 30 constitutively active mutants 
of this receptor, mutations hypothesized to produce distinct active conformations were 
grouped into four abutting areas of the receptor from the extracellular (group I) to the 
intracellular (group IV) domain. Details about the residues that form each group can be 
found in Decaillot FM. A sequential binding mechanism was proposed to activate the 
receptor.(Decaillot, Befort et al. 2003) Sequential binding in GPCRs is not uncommon. A 
similar mechanism has been postulated for the ǃ2-adrenergic receptors.(Swaminath, Xiang 
et al. 2004) In the case of the -opioid receptor agonists bind to residues in group I 
comprising a hydrophobic region in EL3, weakening interactions with TM6 and TM7 in the 
extracellular domain thus initiating a signal. Next, the ligand enters the binding pocket 
disrupting interactions in groups II and III. Group II residues form a molecular switch that 
controls movements of TM3. Group III residues are closest to the binding site, consist of 
patches of hydrophilic and hydrophobic residues and form a network of interactions 
between residues derived from TM3, 6 and 7. The disruption of these interactions results in 
a receptor state that is susceptible to activation and helps propagate signals to the 
intracellular side. It was hypothesized that the amphiphilic nature of opiates and opioid 
ligands makes them complementary to residues in group III, i.e., the hydrophilic portion of 
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the ligands disrupt the hydrogen-bonding network, while the hydrophobic portion compete 
with the hydrophobic residues. Finally, disrupting the interactions in group 4 residues 
results in the separation of TM6 and TM7 in the intracellular side and possibly destabilizing 
interactions with Gǂ and exposure to other secondary protein effectors. 
Insights about the conformation of the activated state of the -opioid receptor are based on 
modeling experimental distance constraints derived from site-directed mutagenesis, inter-
helix H-bonds, disulphide bonds, and engineered Zn2+ binding sites between the -opioid 
receptor and analogues of the receptor-bound conformation of a cyclic tetra-peptidomimetic, 
JOM6.(Fowler, Pogozheva et al. 2004) Structural data for the active state were also derived 
from disulphide bonds between TM5 and TM6 in the ACM3 muscarinic receptor,(Ward SD, 
JBC 2002) intrinsic allosteric Zn2+ binding sites  in TM5 and TM6 of the ǃ2-adrenergic 
receptor,(Swaminath, Lee et al. 2003) engineered activating metal-coordination center akin to 
those between TM3 and TM7 in the ǃ2-adrenergic(Elling, Thirstrup et al. 1999) and 
tachykinin(Holst, Elling et al. 2000) receptors, between TM2 and TM3 of the MC4 melanocortin 
receptor. Finally one hydrogen bond constraint from the ǅ-opioid receptor(Decaillot, Befort et 
al. 2003) was introduced. A comparison between the modeled structures of the active and 
inactive states of the -opioid receptor is shown in Figure 1. A noticeable difference is seen in 
TM6 highlighting the rigid-body movement described for the -opioid receptor. 
2.3 Internalization of opioid receptors and changes in downstream signaling  
Signal transduction by the -opioid receptor is determined by properties of the ligand such 
as affinity, potency, efficacy, bio-availability and half-life, collectively defined as ‘relative 
activity’ or RA.(Martini and Whistler 2007) In addition, the length of time the receptor-
ligand complex remains coupled to the G-protein, is controlled by receptor desensitization, 
endocytosis and to an extent the pharmacokinetic properties of the ligand. It has been noted 
that ligand activity and endocytosis do not have a linear relationship.(Martini and Whistler 
2007) Hence, an interplay of relative activity versus endocytosis (RAVE) for each ligand 
determines the magnitude of the signal transduced. Thus each ligand-receptor complex has 
an associated RAVE value. As highlighted by Martini L et al.(Martini and Whistler 2007) 
endogenous peptides have good RA values at the μ-opioid receptor, and also induce 
significant desensitization and endocytosis. Based on this reasoning, the good balance 
between their RA and VE values explain why they do not induce tolerance. Another 
example is methadone. Methadone has comparable potency with encephalin and is also an 
equally good receptor internalizer.(Whistler, Chuang et al. 1999) Nonetheless, it has a longer 
half-life compared to other opioids, and consequently a larger RA value giving rise to a 
moderately higher RAVE value. The extension of the RAVE analysis to morphine is more 
complicated and invokes secondary protein effectors and region-selective differences in 
receptor endocytosis.(Martini and Whistler 2007) In general, agonists such as morphine with 
high RAVE values are more likely to induce tolerance. It has been demonstrated that the 
development of -opioid tolerance is inversely related to the ability of an agonist to promote 
receptor endocytosis or internalization.(Whistler, Chuang et al. 1999; Finn and Whistler 
2001) This theory distinguishes two types of agonists based on their ability to stabilize 
different receptor conformational states, resulting in phosphorylation by different kinases. 
Depending on the type of kinase the receptor can be rapidly endocytosed, resensitized and 
recycled to the cell surface, preventing the development of tolerance.  
The formation of an opioid ligand-receptor complex results in structural changes at the 
extracellular and transmembrane domains, which are propagated to the intracellular 
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domain followed by the dissociation of G-proteins; phosphorylation by G-protein coupled 
receptor kinases (GRK), protein kinase A (PKA) and C (PKC); and binding by other proteins 
such as ǃ-arrestins.(Eguchi 2004) The phosphorylated receptor is endocytosed, whereby it is 
re-sensitized and recycled to the cell surface or it is marked for degradation. Unlike PKA 
and PKC, specific GRK-phosphorylation triggers the recruitment of ǃ-arrestins, receptor 
internalization, resensitization and recycling to the cell surface. This dynamic recycling 
process has been suggested as crucial to circumvent development to drug tolerance. 
Tolerance-causing agonists impede receptor endocytosis and/or resensitization, while non-
tolerance-inducing drugs promote rapid receptor desensitization-internalization-
resensitization and recycling.(Martini and Whistler 2007)  
The exact cause of development of tolerance is still a subject of debate. Nonetheless, it is 
generally accepted that chronic administration of opiates for analgesia gives rise to 
tolerance. The cellular mechanism of tolerance may involve downstream compensatory 
changes in neuronal circuits.(Eguchi 2004) The continual and sustained inhibition of 
adenylate cyclase activity triggers a positive feedback to compensate for the low 
intracellular levels of cAMP, resulting in the reversible superactivation of adenylate cyclase. 
This up-regulation of enzyme activity restores the cellular concentration of cAMP, resulting 
in cells being tolerant to the opiate and also dependent on it given that withdrawing the 
drug or introducing an antagonist gives rise to abnormally high levels of cAMP and also a 
restoration of the normal activity level of adenylate cyclase.(Sharma, Klee et al. 1975) The 
change is delayed but relatively stable and is known to be responsible for opiate tolerance 
and dependence.(Sharma, Klee et al. 1975) The combined inhibition and up-regulation of 
adenylyl cyclase provide a means of activating and deactivating neuronal circuits and may 
play a role in a memory process. It was later shown that the adenylate cyclase V and GǃǄ 
played a role in this activation.(AvidorReiss, Nevo et al. 1996) 
2.4 Point-mutation studies to identify key residue targets for phosphorylation 
Mutation studies have been successful in identifying key cytosolic domains and residues of 
ligand-activated -opioid receptors, which are liable to phosphorylation, and potentially 
directly involved in agonist-dependent receptor internalization. (Celver, Lowe et al. 2001; El 
Kouhen, Burd et al. 2001; Celver, Xu et al. 2004) Truncation of the -opioid receptor at Ser363 
produced a mutant that was not phosphorylated, and was endocytosed and recycled more 
slowly than the wild-type,(Qiu, Law et al. 2003) suggesting that phosphorylating residues in 
this segment may be important for internalization. Cleaving off the entire C-terminal resulted 
in increased agonist-independent internalization and recycling,(Waldhoer, Bartlett et al. 2004) 
indicating a greater exposure of some residues critical for the dynamic recycling machinery. 
Utilizing a single agonist, [D-Ala2,MePhe4,Gly5-ol]enkephalin (DAMGO), the mutation of 
Thr180 to alanine in the second intracellular loop prevented receptor desensitization, while 
alanine scanning of serine or threonine in the third cytoplasmic loop did not inhibit receptor 
desensitization.(Celver, Lowe et al. 2001) In a DAMGO-induced receptor activation study, 
mutations of C-terminal serine/threonine residues identified three phosphorylation sites: 
Ser363, Thr370 and Ser375. The S375A mutant decreased the rate of receptor internalization, 
while the S363A and T370A double mutant accelerated the rate of internalization,(El Kouhen, 
Burd et al. 2001) which may suggest that the combined phosphorylation of Ser363 and Thr370 
attenuates receptor internalization. Other studies employing etorphine and multiple mutations 
have also identified Ser356 and Ser363,(Burd, El-Kouhen et al. 1998)  and Thr394 (using 
DAMGO)(Pak, Odowd et al. 1997; Wolf, Koch et al. 1999) as sites for phosphorylation that 
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result in down-regulation of the -opioid receptor. Mutation of Ser356 and Ser363 
simultaneously did not alter receptor phosphorylation, but the mutations prevented down-
regulation of the receptor suggesting that the absence of down-regulation was not due to the 
removal of phosphorylation sites. Down-regulation may be occurring through a 
phosphorylation-independent mechanism or these two sites are not phosphorylated. This is 
contrary to later studies that demonstrated that Ser363 is phosphorylated.(El Kouhen, Burd et 
al. 2001) The T394A mutant is more rapidly internalized and resensitized relative to the wild-
type -opioid receptor. These mutation studies show that multiple phosphorylation motifs 
may be needed for internalization and that not every phosphorylation site is phosphorylated. 
3. Discovery and development of opioid receptor ligands 
3.1 Endogenous opioid ligands 
Extensive structural and pharmacological studies have been performed to understand the 
mechanisms of action of opioids as well as for the design of new and more efficient opioid-
based painkillers. The opioid agonists propagate their analgesic effects by interacting with 
opioid receptors. They are both endogenously expressed peptides and exogenous opiates. 
The term opiate is reserved for foreign substances introduced into the body to target opioid 
receptors. The endogenous peptides enkephalins, dynorphins, ǃ-endorphins and 
nociceptins are excised from their precursors pro-enkephalin, pro-dynorphin, pro-
opiomelanocortin and pro-nociceptin/orphanin FQ, respectively. The majority of these 
peptides comprise a conserved N-terminal YGGF motif,(Gentilucci, Squassabia et al. 2007) 
except the uncharacteristically short peptides endomorphin-1 (YPWF-NH2) and 
endomorphin-2 (YPFF-NH2) that are considered analogues of the YGGF motif.  A list of 
endogenous peptides, their precursors and receptor selectivity is presented in Table 1. 
 
Peptide Sequences Precursor Selectivity 
Endomorphin-1 YPWF-NH2 NDa μ 
Endomorphin-2 YPFF-NH2 
ǃ-endorphin YGGFMTSEKSQTPLVTLFK         NAIIKNAYKKGE Pro-opiomelanocortin μ=ǅ 
[Leu5]enkephalin YGGFL 
Pro-enkephalin ǅ [Met5]enkephalin YGGFM 
Metorphinamide YGGFMRRV-NH2 
Deltorphin A YmFHLMD-NH2 
NDa ǅ Deltorphin I YaFDVVG-NH2 
Deltorphin II YaFEVVG-NH2 
Dynorphin A YGGFLRRIRPKLKWDNQ 
Pro-dynorphin κ 
Dynorphin A(1-8)  YGGFLRRI 
Dynorphin B YGGFLRRQFKVVT 
ǂ-neoendorphin YGGFLRKYPK 
ǃ-neoendorphin YGGFLRKYP 
Nociceptin FGGFTGARKSARKLANQ Pro-nociceptin / Orphanin FQ ORL-1b 
a Not yet determined. The conserved YGGF sequence is shown in bold 
b Orphan opioid receptor-like 1 
Table 1. Endogenous opioid peptides, the precursor and receptor selectivity. 
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Endomorphin-1 and endomorphin-2 are highly potent, selective μ-opioid receptor 
endogenous peptides isolated from mammals, and elicit responses similar to that of 
morphine.(Zadina, Hackler et al. 1997; Horvath 2000) The endogenous peptides are 
advantageous in that they do not display any of the side effects of opiates (see below); 
however, they are not effective in clinical settings because of in vivo degradation by 
peptidases.(Witt, Gillespie et al. 2001) Notwithstanding their degradation, these peptides 
and their analogues have been utilized extensively as tools to probe receptor categorization 
and structure-activity relationships.(Hruby and Agnes 1999; Gentilucci, Squassabia et al. 
2007) The exogenous opiates on the other hand are more effective in pain management, but 
present numerous undesirable side effects, some of which are highlighted below. As such, 
several efforts are being undertaken to identify beneficial analgesics with minimal to no side 
effects. 
3.2 Potent opioid-based analgesics 
Interests in identifying more effective analgesics have led to the reporting of a large number 
potent opioid peptide and non-peptide compounds that are generally classified as agonists 
or antagonists.(Pan 1998; Stevens, Jones et al. 2000; Eguchi 2004; Waldhoer, Bartlett et al. 
2004; Gentilucci, Squassabia et al. 2007; Prisinzano and Rothman 2008; Volpe, Tobin et al. 
2011) In spite of the multitude of known opioid compounds, only a relatively small number 
has been approved for clinical use. The majority of these prescribed analgesics are relatively 
selective for the μ-opioid receptor,(Volpe, Tobin et al. 2011) though at sufficiently higher 
doses interactions with the other opioid receptors will occur. While some of these 
compounds are selective for either the μ (morphine), κ (salvinorin A), or ǅ (naltrindole) 
opioid receptors, some are non-selective and display mixed agonist/antagonist responses, 
for example buprenorphine, pentazocine and butorphanol. Buprenorphine is a partial μ-
agonist and partial κ-antagonist that is administered clinically for opioid detoxification and 
maintenance.(Blakeney, Reid et al. 2007)  
 
Compound Receptor Functiona Compound Receptor Functiona 
Morphine* Μ A Cyclazocine* μ/κ A/AN 
Fentanyl* “ “ Pentazocine* “ “ 
Hydrocodone* “ “ Nalbuphine* “ “ 
Levorphanol* “ “ SIOM Δ A 
Meperidine* “ “ SCN-80 “ “ 
Sufentanyl* “ “ TAN-67 “ “ 
Methadone* “ “ Ketocyclazocine Κ A 
Oxycodone* “ “ Ethyl Ketocyclazocine “ “ 
Oxymorphone* “ “ U-50,488 “ “ 
Codeine* “ “ Salvinorin A “ “ 
Naloxone* “ AN 6’-GNTIa “ “ 
Buprenorphine* μ/κ A/AN 5’-GNTIa “ AN 
Butorphanol* “ “ Bremazocine μ/ǅ/κ A/AN 
A = agonist; AN = antagonist 
*Currently in clinical use. a GNTI: guanidino-naltrindole   
Table 2. Opioid receptor ligands. 
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Fig. 2. The chemical structures of some exogenous opiates. The classical “message” tyramine 
moiety is colored in red in the structure of morphine. 
The classification of some opioid compounds is given in Table 2. The chemical structures of 
selected compounds are shown in Figure 2. Several factors affect the potency of an analgesic, 
including route of administration, whether they act as full or partial agonists, ability to cross 
the blood-brain barrier (physico-chemical properties) and their effects on other major 
physiological systems.(Volpe, Tobin et al. 2011) Some potency comparisons with morphine 
worth mentioning include the following: fentanyl when administered intramuscularly is 
about 100 fold more potent; hydromorphone is 6-8 fold more potent;(Inturrisi 2002) and oral 
oxycodone is about 1.8 times more potent.(Curtis, Johnson et al. 1999) Though a partial 
agonist buprenorphine is reported to be 25-40 times more potent than morphine.(Blakeney, 
Reid et al. 2007) 
3.3 Pharmacophoric features of opioid ligands 
Numerous structure-activity relations (SAR) studies have been carried out on opioid 
receptor ligands to determine features that drive affinity or efficacy with the goal of 
generating more effective therapeutic compounds,(Eguchi 2004; Metcalf and Coop 2005; 
Prisinzano and Rothman 2008; Yongye, Appel et al. 2009, amongst others). SAR studies 
employing site-directed substitutions and constraints of endogenous peptides, as well as 
modifications of morphine have provided valuable insights about the pharmacophoric 
features, ligand selectivity and biological roles of opioid receptors.(Blakeney, Reid et al. 
2007) For example it has been determined that a positively charged amine group, an 
aromatic moiety and a hydrophobic group result in tight binding of morphine. A salt-
bridge is formed between the protonated amine and an aspartate residue in TM3, π-π 
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stacking interactions between the aromatic group and residues in the binding pocket and 
hydrophobic-hydrophobic interactions. In endogenous peptides the N-terminal tyrosine 
contains a protonated amine and aromatic group, akin to the aromatic ring (A) and basic 
nitrogen (N) in morphine, Figure 3. This moiety termed tyramine is common to a majority 
of opioids, though there are some notable potent and selective opiates that lack this 
classical pharmacophore: Salvinorin A was the first highly potent, non-nitrogen opiate 
agonist selective towards the -opioid receptor;(Roth, Baner et al. 2002) one of its 
analogues, herkinorin became the first non-nitrogenous agonist selective towards the -
opioid receptor.(Harding, Tidgewell et al. 2005) Furthermore, the phenylalanine side 
chain in endogenous peptides mimics the hydrophobic feature (B) of morphine (ring C). It 
should be pointed out that due to size differences between the peptides and morphine, 
the interactions between their respective hydrophobic features (B) and the receptor are 
different.  
The observation of the occurrence of a common structural feature amongst opioid ligands 
gave rise to the “message-address” concept of ligand-receptor interactions, i.e., the same 
message (signal transduction) is delivered to different addresses (receptors). For the 
endogenous peptides the message comprises the conserved YGGF motif, with the 
exceptions cited in Table 1, while for the opiates the tyramine moiety represents the 




Fig. 3. Chemical structures of morphine and the truncated “message” motif of an 
endogenous peptide. The YGGF represents amino acids: Y, tyrosine; G, glycine and F, 
phenylalanine. 
Generating pharmacophore models for opioid receptors have followed two traditional 
approaches: ligand-based or docking-based. Ligand-based methods involve identifying and 
superimposing common substructures of low energy conformers from which features that 
drive biological activity are determined. However, because of the inherent difficulties of 
superimposing structurally different scaffolds these efforts have typically revolved around 
congeneric series. See Shim J et al.(Shim, Coop et al. 2011) and references therein. In ligand-
based virtual screenings via multi-conformer ensembles, the quality and coverage of the 
conformational ensemble are important. The production of the conformers can be 
computationally intensive, especially for compounds with a large number of rotatable 
bonds. Thus, reducing the size of multi-conformer databases and the number of query 
conformers, while simultaneously reproducing the bioactive conformer with good accuracy, 
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is of crucial interest. A recent protocol that takes into account these aspects has been 
proposed.(Yongye, Bender et al. 2010) This protocol and other important aspects of 
conformational coverage in ligand-based virtual screening methods have been recently 
revised.(Musafia and Senderowitz 2010) On the other hand, docking-based approaches are 
most valuable when experimental structures of receptors are available. The absence of 
experimental opioid receptor structures means docking-based methods must rely on 
homology models. Moreover, for docking-based virtual screening, one has to contend with 
no induced fit and the possibility of different binding modes.  
The identification of enkephalins and -opioid receptors fueled interests in developing 
ligands that target this receptor. The observation that co-administration of -opioid receptor 
antagonists with -opioid receptor agonists produced analgesia without the side effect of -
only agonists further served as motivation to identify -selective opioids. Hence, 
considerable efforts have been devoted to studying the SAR of -opioid receptor ligands 
using both pharmacophore and quantitative structure-activity relationship modeling. See 
Bernard D et al.(Bernard, Coop et al. 2007) and references therein. Employing the 
conformationally sampled pharmacophore (CSP) approach Bernard D et al. were able to 
differentiate between -opioid receptor agonists and antagonists.(Bernard, Coop et al. 2003; 
Bernard, Coop et al. 2005) An advantage of the CSP method is the inclusion of high energy 
conformers in describing pharmacophores, the justification stemming from the fact that 
ligands may bind in higher energy conformers stabilized by intermolecular interactions with 
receptors. The CSP methodology was later applied to peptide and nonpeptide agonists to 
derive pharmacophore models of -opioid receptor ligands.(Bernard, Coop et al. 2007) Three 
pharmacophore points were considered: aromatic (A), basic nitrogen (N) and hydrophobic 
group (B). 
Utilizing efficacy as the activity index, CSP was extended to five peptides and twenty 
nonpeptides comprising -opioid receptor ligands, to derive an aggregate pharmacophore. 
By analyzing a diverse group of agonists, partial agonists and antagonists the following 
conclusions were derived: interactions with the B or hydrophobic site of oripavines 
(etorphine, buprenorphine and diprenorphine) modulated the degree of agonism; agonists 
with bulky B groups adopt a pose in which interactions occur with both the basic amine and 
the B site; agonists with large N-substituents are oriented such that the substituents occupy 
the position of the traditional B site. The resultant pharmacophore is an aromatic group (A), 
a basic amine (N), a hydrophobic group (B) and N-substituents (S). The investigators claim 
that such an approach would facilitate efforts to develop compounds that possess both μ-
agonistic and ǅ-antagonistic properties even though the cell lines only expressed the μ-
opioid receptor.(Shim, Coop et al. 2011) Furthermore, depending on the structural class of 
the ligand, N-subsituents can enhance agonism or antagonism. For example, N-allyl and N-
cyclopropylmethyl substituents in etorphines give rise to better agonists compared to 
morphine,(Gorin and Marshall 1977) while they induce antagonism in 4,5-
epoxymorphinans.(Shim, Coop et al. 2011) 
The currently known -opioid receptor agonists have been classified into eight structural 
classes(Yamaotsu and Hirono 2011): peptides (dynorphins), benzomorphans (pentazocine), 
morphinans (butorphanol), arylacetamines (U-69593), diazabicyclononanones (HZ2), 
bicyclic guanidines (TPI-614-1), benzodiazepines (±tifluadom) and neocleorodane 
diterpenes (salvinorin A). A comprehensive review of these classes and the history of the 
development of -opioid receptor ligand pharmacophores was published recently by 
Yamaotsu N et al.(Yamaotsu and Hirono 2011) Evidently, the structural diversity of these 
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classes making it difficult to construct a consensus pharmacophore model. Previous SAR 
and pharmacophore analyses of -opioid receptor ligands are typically confined to 
structural analogues. Yamaotsu N et al. proposed a consensus pharmacophore 
encompassing all eight classes using seven compounds in both the training and test sets. 
Superposition was based on the physico-chemical properties of groups of atoms. The 
consensus pharmacophore comprised three hydrophobic groups, a hydrogen bond donor 
and three hydrogen bond acceptors. These pharmacophoric features were employed to 
describe four binding orientations of the different classes of ligands for the -opioid 
receptor. It remains to be determined how this consensus pharmacophore will perform in 
virtual screening: for example screening a database, requiring that a given number of 
features match, followed by biological evaluation of the top scoring compounds. 
Additionally, in the search of opioid receptor ligands, structure similarity(Martinez-
Mayorga, Medina-Franco et al. 2008; Yongye, Appel et al. 2009) and chemoinformatic 
analyses(Medina-Franco, Martínez-Mayorga et al. 2009) have been employed to develop 
SAR and to characterize highly dense combinatorial libraries. 
3.4 Identification of opioid receptor ligands 
A large and growing body of literature has reported the identification of opioid receptor 
ligands. In particular, improvements in high-throughput chemical synthesis have made 
possible the rapid and efficient generation of molecules, giving rise to thousands or millions 
of compounds in combinatorial libraries. Advances in molecular biology have also enabled 
the evaluation of millions of individual compounds against a number of different biological 
targets via high-throughput screening (HTS). However, some high content assays, such as in 
vivo studies, are not amenable to the high-throughput miniaturization required to screen 
millions of individual compounds.  In such cases, screening libraries using a mixture-based 
format(Houghten, Pinilla et al. 1999; Pinilla, Appel et al. 2003; Houghten, Dooley et al. 2006) 
(also known as positional scanning-synthetic combinatorial libraries or PS-SCL) enables the 
evaluation of thousands to millions of molecules in approximately a hundred to a few 
hundred samples. PS-SCL have been used to successfully identify active molecules for a 
variety of biological targets. (Houghten, Pinilla et al. 1999; Pinilla, Appel et al. 2003; 
Houghten, Pinilla et al. 2008) In the case of opioid receptors highly active peptides (Dooley, 
Chung et al. 1994; Houghten, Dooley et al. 2006) and peptidomimetics have been identified. 
(Houghten, Dooley et al. 2006)  This technique has recently found new applications in the 
search of conotoxins (Armishaw, Singh et al.) and in-vivo screening (Reilley, Giulianotti et 
al.). A step forward in the development of peptides with therapeutic relevance corresponds 
to the formation of cyclic structures. Cyclic peptides are therapeutically attractive due to 
their high bioavailability, potential selectivity, and scaffold novelty. In addition, the 
presence of D-residues induces conformational preferences not followed by peptides 
consisting of only naturally abundant L-residues.  Therefore, the development of synthetic 
schemes and comprehending how amino acids induce turns in peptides is significant in 
peptide design. For example, a successful method for the synthesis of cyclic peptides by the 
intramolecular aminolysis of peptide thioesters, has been recently reported,(Li, Yongye et al. 
2009) and the corresponding explicit solvent molecular dynamics simulations were 
produced and analyzed.(Yongye, Li et al. 2009) The cyclic tetra-peptidomimetic, JOM6, 
(Fowler, Pogozheva et al. 2004) is an example of a conformationally constrained peptide that 
retains activity against the -opioid receptor. It is anticipated that research will continue in 
this direction.  
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The search of opioid receptor ligands using experimental screening of combinatorial 
libraries has been complemented using computational methods. In silico methods can be 
incorporated at different stages of the drug discovery process, from library design to lead 
optimization. (Brooijmans and Kuntz 2003) Computational methods are largely applied to 
corporate chemical collections (Bajorath 2002) as well as combinatorial chemical libraries. 
(Houghten, Pinilla et al. 2008) However, limited efforts have been reported so far to 
explicitly integrate information from mixture-based combinatorial libraries and 
computational techniques (López-Vallejo, Caulfield et al. 2011; Yongye, Pinilla et al. 2011). 
The structural analogy contained in combinatorial libraries in general and in mixture-based 
libraries in particular deserves particular considerations. Virtual screening may assist in 
downsizing large compound libraries and the selection of a smaller set of promising hits, 
whereas mixture-based screening may screen out some of the false positives of virtual 
screening. The integration of mixture-based combinatorial library screening data and virtual 
screening information has been undertaken. In the particular case of opioid receptors, the 
predicted activity obtained from the experimental mixture-based screening of a large library 
of bicyclic guanidines was combined with structural similarity methods. This approach 
allowed categorizing the molecules as actives, activity cliffs, diverse compounds and missed 
hits.(Yongye, Pinilla et al. 2011) 
4. Conclusions 
Ever since the discovery of opioid receptors as the principal mediators of analgesia and the 
identification of endogenous peptides as well as opiates that elicit analgesic responses, 
considerable efforts have been devoted to finding compounds that target these receptors 
with the aim of alleviating the sensation of pain. While the endogenous peptides do not 
display any side effects, their use in clinical settings is hampered because of in vivo 
degradation by protein-digesting enzymes. Opiates are more effective, but adverse side 
effects such as tolerance, dependence and addiction limit their prolonged usage; thus the 
continual search for more efficient analgesics. Several compounds have been reported as 
opioid receptor ligands, however, only a relatively few are currently prescribed in clinical 
settings with morphine being the prototypical -opioid agonist. A high proportion of 
opioid-based drugs is selective toward the μ-opioid receptor, and still retains untoward side 
effects prompting extensive studies about the molecular origins of these undesirable 
properties.  
This review focuses on structural aspects of opioid receptors and opioid receptor ligands, 
with special emphasis on the -opioid receptor. The information presented here can be 
summarized as follows: 
1. Considerable evidence now point to the existence of opioid receptors as homo- or 
hetero-oligomeric complexes and that their pharmacological responses may be cross-
modulated. For example the co-administration of a -opioid agonist with a ǅ-opioid 
antagonist suppressed side effects such as dependence and tolerance while retaining -
agonist induced analgesia. The realization of this potential for cross-modulation has 
generated interests in the development of bivalent ligands. The ligands may be 
individual compounds that possess mixed agonist/antagonist properties or a separate 
agonist and antagonist tethered through a linker. Future directions of research in 
analgesia will continue to point towards agonists with acceptable side effects, designing 
bivalent ligands, or ligands with mixed receptor specificities and functions. 
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2. While the exact mechanisms of development of tolerance are still under debate, the 
current models suggest a combination of ligand-induced conformational changes and 
receptor desensitization, as well as down-stream compensatory changes of secondary 
effectors. 
3. Promising computational methods such as consensus pharmacophore models using 
different structural scaffold might serve a role in identifying ligands with mixed 
secondary functional profiles. Understanding the cross-talk between the different 
signaling pathways of the opioid receptors will also be significant. 
4. Production and analysis of a large number of compounds with potential affinity to 
opioid receptors are possible. However, considerably more work will need to be done 
to understand and design compounds with high analgesic effect and lower side effects. 
To that end, a more detailed understanding of the signaling process upon opioid 
receptor activation is needed.  
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